Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.86
- Piotroski Score 4.00
- Grade Buy
- Symbol (PSTI)
- Company Pluristem Therapeutics Inc.
- Price $1.00
- Changes Percentage (-2.91%)
- Change -$0.03
- Day Low $0.96
- Day High $1.04
- Year High $0.00
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 09/12/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.46
- Trailing P/E Ratio -0.68399452804378
- Forward P/E Ratio -0.68399452804378
- P/E Growth -0.68399452804378
- Net Income $-49,865,000
Income Statement
Quarterly
Annual
Latest News of PSTI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The 11 Best Nude Lipsticks, According To Makeup Artists
Discover the top nude lipsticks like Kevyn Aucoin Unforgettable Lipstick and Hermès Satin Lipstick that enhance your natural lips and complement your makeup look. Consider your undertones and lip col...
By Forbes | 2 weeks ago -
This Lip Crayon Has the Best Qualities of a Lipstick and Lip Liner -- and It Was Just Used on Chrissy Teigen
John Legend's upcoming album might feature a song about Chrissy Teigen's lips. Teigen was seen using Ilia Beauty's Lip Sketch Hydrating Crayon, a popular product praised for its creamy, hydrating form...
By PEOPLE.com | 3 weeks ago -
JD Vance says Jack Smith's indictment is "classic lipstick on a pig"
A new indictment filed by Smith against Trump reworks four felony counts related to the 2020 election. The indictment refers to Pence as Trump's "running mate" but also as "vice president." Trump and ...
By Newsweek | 1 month ago
